ConductScience.org, home

Paper11238696

Targeting ceramide metabolism--a strategy for overcoming drug resistance.

Senchenkov A and 2 others. J Natl Cancer Inst, 2001. Cited by 240 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targeting ceramide metabolism--a strategy for overcoming drug resistance. Papers, record 11238696. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11238696

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting ceramide metabolism--a strategy for overcoming drug resistance.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
2001
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
240
iCite
Relative citation ratio, by iCite
5.22
iCite
Revised in PubMed
2019-05-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Senchenkov AA
2Litvak DAD A
3Cabot MCM C

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CeramidesMajor topic
Drug Resistance, NeoplasmMajor topic
NeoplasmsMajor topic
SphingosineMajor topic
Animals
Apoptosis
Drug Resistance, Multiple
Glucosylceramides
Humans
Signal Transduction
Sphingomyelins

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CA77632NCI NIH HHSUnited StatesR01CA077632PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Cited by108

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 240 citations.

PMIDTitleJournalYearIn PapersSource
42151151DKC1 promotes colorectal cancer progression and therapy resistance by dysregulating sphingolipid biosynthesis.Nat Commun2026https://conductscience.org/library/papers/42151151PubMed
41346814Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm.Discoveries (Craiova)2025https://conductscience.org/library/papers/41346814PubMed
41305332Pathogens That Rewrite the Rules: Ascoviruses, Elegant Manipulators of Cell Death Pathways and Architects of the Extracellular Viral Paradigm.Pathogens2025https://conductscience.org/library/papers/41305332PubMed
40880617The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics.J Oncol Res Ther2024https://conductscience.org/library/papers/40880617PubMed
40088396Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings.Cancer Metastasis Rev2025https://conductscience.org/library/papers/40088396PubMed
39397024A sphingolipid rheostat controls apoptosis versus apical cell extrusion as alternative tumour-suppressive mechanisms.Cell Death Dis2024https://conductscience.org/library/papers/39397024PubMed
39337463Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.Int J Mol Sci2024https://conductscience.org/library/papers/39337463PubMed
39337312The Drug Transporter P-Glycoprotein and Its Impact on Ceramide Metabolism-An Unconventional Ally in Cancer Treatment.Int J Mol Sci2024https://conductscience.org/library/papers/39337312PubMed
39125841Sphingosine 1-Phosphate Stimulates ER to Golgi Ceramide Traffic to Promote Survival in T98G Glioma Cells.Int J Mol Sci2024https://conductscience.org/library/papers/39125841PubMed
39072358Application of sphingolipid-based nanocarriers in drug delivery: an overview.Ther Deliv2024https://conductscience.org/library/papers/39072358PubMed
38203654Central Role of β-1,4-GalT-V in Cancer Signaling, Inflammation, and Other Disease-Centric Pathways.Int J Mol Sci2023https://conductscience.org/library/papers/38203654PubMed
38136410Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/38136410PubMed
38078003Sphingolipids in mitochondria-from function to disease.Front Cell Dev Biol2023https://conductscience.org/library/papers/38078003PubMed
37335416Solid tumor treatment via augmentation of bioactive C6 ceramide levels with thermally ablative focused ultrasound.Drug Deliv Transl Res2023https://conductscience.org/library/papers/37335416PubMed
36831326Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity.Cells2023https://conductscience.org/library/papers/36831326PubMed
36567598Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer.Technol Cancer Res Treat2022https://conductscience.org/library/papers/36567598PubMed
36142562Ceramide Metabolism Regulated by Sphingomyelin Synthase 2 Is Associated with Acquisition of Chemoresistance via Exosomes in Human Leukemia Cells.Int J Mol Sci2022https://conductscience.org/library/papers/36142562PubMed
35487785Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.Blood Rev2022https://conductscience.org/library/papers/35487785PubMed
35004331The Role of Sphingolipids Metabolism in Cancer Drug Resistance.Front Oncol2021https://conductscience.org/library/papers/35004331PubMed
34888943Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia.FASEB J2022https://conductscience.org/library/papers/34888943PubMed

See all 108 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11238696

GET https://conductscience.org/api/papers/v1/11238696/cited_by?page=2